NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Forecast & News

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Sorrento Therapeutics Inc (NASDAQ:SRNE) released its quarterly earnings results on Friday, November, 8th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.42). The biopharmaceutical company earned $5.78 million during the quarter, compared to the consensus estimate of $7.70 million. Sorrento Therapeutics had a negative net margin of 1,101.69% and a negative return on equity of 193.12%. View Sorrento Therapeutics' Earnings History.

Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Sorrento Therapeutics.

3 analysts have issued 1-year price targets for Sorrento Therapeutics' shares. Their forecasts range from $12.00 to $30.00. On average, they expect Sorrento Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 441.2% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.

News stories about SRNE stock have trended somewhat negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Sorrento Therapeutics.

Some companies that are related to Sorrento Therapeutics include National Research (NRC), Geovax Labs (GOVX), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX) and Vitality Biopharma (VBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Amarin (AMRN), Cara Therapeutics (CARA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Viking Therapeutics (VKTX) and Canopy Growth (CGC).

Sorrento Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.09%), Donald L. Hagan LLC (0.01%), Alpine Global Management LLC (0.01%) and Pegasus Asset Management Inc. (0.01%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd and George K Ng. View Institutional Ownership Trends for Sorrento Therapeutics.

SRNE stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Donald L. Hagan LLC, Alpine Global Management LLC and Pegasus Asset Management Inc.. View Insider Buying and Selling for Sorrento Therapeutics.

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SRNE stock can currently be purchased for approximately $3.88.

Sorrento Therapeutics has a market capitalization of $651.06 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.

The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com/.

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]